Patents Assigned to Bioscience, Inc.
  • Methods of lowering serum cholesterol
    Patent number: 10293043
    Abstract: Methods of treating subjects having diseases, disorders, or conditions, including disorders associated with cholesterol homeostasis, responsive to agents modulating Kupffer cell function, including methods of administration and dosing regimens associated therewith, are provided. Methods of treating subjects having liver diseases, disorders, or conditions, including non-alcoholic steatohepatitis and non-alcoholic fatty liver disease, with an IL-10 agent are also provided.
    Type: Grant
    Filed: May 6, 2015
    Date of Patent: May 21, 2019
    Assignee: Armo Biosciences, Inc.
    Inventors: John Brian Mumm, Ivan Ho Chan
  • Methods and systems for ultra-sensitive detection of genomic alterations
    Patent number: 10294518
    Abstract: The invention discloses methods and apparatuses for the detection and diagnostics of genetic alterations/mutations in a target sample, which may be a solid tissue or a bodily fluid. A reference sample is also acquired, and the target and reference samples are replicated into multiple target and reference replicates. The replicates are sequenced, and the sequence data is analyzed based on a statistical test. The statistical test compares the measurements between the target and reference replicates at respective allelic indices. True positive calls are then made based on the results of the statistical testing, and the desired genetic alterations/mutations are identified at the base-pair level. The invention may be used for diagnostics related to cancer, auto-immune disease, organ transplant rejection, genetic fetal abnormalities and pathogens.
    Type: Grant
    Filed: September 16, 2016
    Date of Patent: May 21, 2019
    Assignee: Fluxion Biosciences, Inc.
    Inventors: Nicholas Kamps-Hughes, Cristian Ionescu-Zanetti
  • ENGINEERED NUCLEASES USEFUL FOR TREATMENT OF HEMOPHILIA A
    Publication number: 20190142973
    Abstract: The present invention encompasses engineered nucleases which recognize and cleave a recognition sequence within the int22h-1 sequence of a Factor VIII gene. The present invention also encompasses methods of using such engineered nucleases to make genetically-modified cells, and the use of such cells in a pharmaceutical composition and in methods for treating hemophilia A. Further, the invention encompasses pharmaceutical compositions comprising engineered nuclease proteins, nucleic acids encoding engineered nucleases, or genetically-modified cells of the invention, and the use of such compositions for treating of hemophilia A.
    Type: Application
    Filed: May 3, 2017
    Publication date: May 16, 2019
    Applicant: Precision BioSciences, Inc.
    Inventors: Derek Jantz, James Jefferson Smith, Victor Bartsevich, Clayton Beard, Michael G. Nicholson
  • METHODS AND COMPOSITIONS FOR NUCLEOSIDE TRIPHOSPHATE AND RIBONUCLEIC ACID PRODUCTION
    Publication number: 20190144489
    Abstract: Provided herein, in some embodiments, are methods and composition for the production of nucleoside triphosphates and ribonucleic acids.
    Type: Application
    Filed: November 20, 2018
    Publication date: May 16, 2019
    Applicant: GreenLight Biosciences, Inc.
    Inventors: Drew S. Cunningham, Daniel MacEachran, James Robbins Abshire, Himanshu Dhamankar, Ifeyinwa Iwuchukwu, Mehak Gupta, Matthew Eduardo Moura, Naveen Sudharsan, Nicholas Skizim, Rachit Jain, Karthikeyan Ramachandriya
  • HPV PARTICLES AND USES THEREOF
    Publication number: 20190142925
    Abstract: The invention relates to modified HPV particles that can be used therapeutically. Modified HPV particles may be used to deliver therapeutic agents, including siRNA molecules. Modified HPV particles may be used for the treatment of diseases or conditions of mucosal tissue, including HPV (human papilloma virus) infection and HPV-related tumors.
    Type: Application
    Filed: November 29, 2018
    Publication date: May 16, 2019
    Applicants: INSERM (Institut National de la Santé et de la Recherche Médicale), Aura Biosciences, Inc.
    Inventors: Pierre L. Coursaget, Antoine A. Touzé, Maxime J.J. Fleury, Nicolas Combelas, Elisabet de los Pinos
  • Methods of manufacturing stable aqueous formulations of adalimumab
    Patent number: 10286072
    Abstract: The invention provides aqueous pharmaceutical adalimumab compositions suitable for long-term storage of adalimumab, methods of manufacture of these compositions, methods of administration, and kits containing same.
    Type: Grant
    Filed: October 10, 2017
    Date of Patent: May 14, 2019
    Assignee: Coherus Biosciences, Inc.
    Inventors: Mark Manning, Robert W. Payne
  • Syringe containing stable aqueous formulations of adalimumab
    Patent number: 10286071
    Abstract: The invention provides aqueous pharmaceutical adalimumab compositions suitable for long-term storage of adalimumab, methods of manufacture of these compositions, methods of administration, and kits containing same.
    Type: Grant
    Filed: October 10, 2017
    Date of Patent: May 14, 2019
    Assignee: Coherus Biosciences, Inc.
    Inventors: Mark Manning, Robert W. Payne
  • Recognition sequences for I-CreI-derived meganucleases and uses thereof
    Patent number: 10287626
    Abstract: Methods of cleaving double-stranded DNA that can be recognized and cleaved by a rationally-designed, I-CreI-derived meganuclease are provided. Also provided are recombinant nucleic acids, cells, and organisms containing such recombinant nucleic acids, as well as cells and organisms produced using such meganucleases. Also provided are methods of conducting a custom-designed, I-CreI-derived meganuclease business.
    Type: Grant
    Filed: March 28, 2017
    Date of Patent: May 14, 2019
    Assignee: Precision BioSciences, Inc.
    Inventors: Derek Jantz, James Jefferson Smith
  • Polynucleotide conjugates and methods for analyte detection
    Patent number: 10288608
    Abstract: The present disclosure provides polynucleotide conjugates, methods, and assay systems for use in detecting the presence, absence, and/or amount of an analyte in a sample. Various polynucleotide conjugates, conjugate pairs, sets, libraries, and assay systems comprising the same are disclosed. In particular, methods and assay systems for antibody detection and analysis are provided. For example, assays capable of high levels of multiplexing are used for antibody detection and analysis in a biological sample, e.g., Lyme disease patient samples. The presently disclosed polynucleotide conjugates, methods, and assay systems can be used to provide sensitive and reliable diagnosis, even at early stages of a disease or condition. Use for monitoring disease progression and prognosis is also disclosed.
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: May 14, 2019
    Assignee: Prognosys Biosciences, Inc.
    Inventors: Igor A. Kozlov, John Andrew Altin, Petr Capek, Mark S. Chee
  • Compositions and methods for inhibiting arginase activity
    Patent number: 10287303
    Abstract: The disclosure relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the disclosure. Also provided herein are methods of treating cancer with the arginase inhibitors of the disclosure.
    Type: Grant
    Filed: December 22, 2017
    Date of Patent: May 14, 2019
    Assignee: Calithera Biosciences, Inc.
    Inventors: Eric B. Sjogren, Jim Li, Lijing Chen, Roland J. Billedeau, Timothy F. Stanton, Michael Van Zandt, Darren Whitehouse, Gunnar E. Jagdmann, Jr., Lene Raunkjær Petersen
  • COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALLERGY
    Publication number: 20190134107
    Abstract: Provided herein are compositions and methods for the treatment of allergy, such as food allergy. Also provided herein are compositions and methods for modulating an immune response associated with allergy and/or inducing immune tolerance or desensitization to an allergy, such as a food allergy.
    Type: Application
    Filed: December 21, 2018
    Publication date: May 9, 2019
    Applicant: Vedanta Biosciences, Inc.
    Inventors: Rose L. Szabady, Bernat Olle, Bruce Roberts
  • COMPOSITIONS CONTAINING COMBINATIONS OF BIOACTIVE MOLECULES DERIVED FROM MICROBIOTA FOR TREATMENT OF DISEASE
    Publication number: 20190134179
    Abstract: Compositions consisting of bioactive molecules derived from the microbiota of a mammal are provided herein. When administered orally with a colonic delivery system, the compositions are useful for the prophylaxis and treatment of diseases, in particular inflammatory, autoimmune and infectious diseases. The compositions comprise combinations of small molecules and bacterial antigens formulated in colonic delivery systems. Use of the compositions results in any or all of: induction of immune tolerance; strengthening of the gut mucosal barrier integrity; reduction of inflammation; and amelioration of a disease state caused by inflammation, an autoimmune reaction or an infectious agent.
    Type: Application
    Filed: October 15, 2018
    Publication date: May 9, 2019
    Applicants: Vedanta Biosciences, Inc., Riken
    Inventors: Kenya Honda, Bernat Olle, Koji Atarashi, Takeshi Tanoue, Hiroshi Ohno, Shinji Fukuda, Koji Hase
  • MODULATORS OF CELLULAR ADHESION
    Publication number: 20190134022
    Abstract: The present invention provides compounds having formula (I): and pharmaceutically acceptable derivatives thereof, wherein R1-R4, n, p, A, B, D, E, L and AR1 are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1).
    Type: Application
    Filed: October 26, 2018
    Publication date: May 9, 2019
    Applicant: SARcode Bioscience Inc.
    Inventors: Wang SHEN, Kenneth BARR, Johan D. OSLOB, Min ZHONG
  • Multiple layer gel
    Patent number: 10281425
    Abstract: A multiple layer gel and method for forming a multiple layer gel are provided. The multiple layer gel includes an isolation layer and an electrolyte layer. The isolation layer provides a molecular weight screen, to prevent proteins or other molecules from contacting a reference cell covered by the isolation layer. The electrolyte layer covers the isolation layer, and provides a source of ions that place the reference cell in ionic and/or electrical contact with a fluid sample. The multiple layer gel can be used to maintain a reliable reference voltage from an associated reference cell while an electrical potential or other electrical characteristic of a sample fluid is being determined.
    Type: Grant
    Filed: May 18, 2016
    Date of Patent: May 7, 2019
    Assignee: Aytu BioScience, Inc.
    Inventors: Raphael Bar-Or, David Bar-Or, Leonard T. Rael
  • Combination therapy with glutaminase inhibitors
    Patent number: 10278968
    Abstract: The invention relates to methods of treating cancer or myeloproliferative diseases with a combination of a glutaminase inhibitor and an anticancer agent selected from cabozantinib, crizotinib, and axitinib. The invention further relates to methods of treating cancer or myeloproliferative diseases that are resistant to one or more anticancer agents.
    Type: Grant
    Filed: August 25, 2017
    Date of Patent: May 7, 2019
    Assignee: Calithera Biosciences, Inc.
    Inventors: Francesco Parlati, Keith Orford, Sam H. Whiting
  • METHOD OF MULTI-GENE ABSOLUTE QUANTIFICATION FOR PCR ARRAY
    Publication number: 20190127787
    Abstract: A method of multi-gene absolute quantification for PCR array is provided, wherein a nucleic acid sample to be tested includes at least one kind of nucleic acid target. Primers for amplifying a plurality of standard DNA or the nucleic acid target to be tested are respectively disposed in a plurality of reaction wells of a test carrier. Afterwards, the plurality of standard DNA with known copy number and the nucleic acid sample are mixed and added into the reaction wells, and qPCR is performed on the standard DNA and the nucleic acid sample. A sequence-specific combination of a forward primer and a reverse primer is designed for each standard DNA, and the same DNA template sequence is presented between regions corresponding to the forward primer and the reverse primer. The primers for amplifying standard DNA and the nucleic acid target to be tested have similar amplification efficiencies.
    Type: Application
    Filed: November 1, 2018
    Publication date: May 2, 2019
    Applicant: Quark Biosciences, Inc.
    Inventors: Ming-Chou Lee, You-Xiu Zheng
  • Recognition sequences for I-CreI-derived meganucleases and uses thereof
    Patent number: 10273524
    Abstract: Methods of cleaving double-stranded DNA that can be recognized and cleaved by a rationally-designed, I-CreI-derived meganuclease are provided. Also provided are recombinant nucleic acids, cells, and organisms containing such recombinant nucleic acids, as well as cells and organisms produced using such meganucleases. Also provided are methods of conducting a custom-designed, I-CreI-derived meganuclease business.
    Type: Grant
    Filed: March 28, 2017
    Date of Patent: April 30, 2019
    Assignee: Precision BioSciences, Inc.
    Inventors: Derek Jantz, James Jefferson Smith
  • Compositions and methods for inhibiting ?-lactamase
    Patent number: 10273235
    Abstract: Substituted dihydroisoxazole derivatives useful as inhibitors of ?-lactamases are provided. The invention further provides medical uses of substituted dihydroisoxazole derivatives, for example, as antibacterial agents.
    Type: Grant
    Filed: March 9, 2018
    Date of Patent: April 30, 2019
    Assignee: LegoChem Biosciences, Inc.
    Inventors: Hye Kyung Chang, Sung Yoon Baek, Min Jung Kim, Kyu Man Oh, Jeung Soon Choi, Soo Bong Ha, Sung Min Kim, Chul-woong Chung, Dae Hyuck Kang, Hyun Jin Kwon, Young Lag Cho, Yong Zu Kim
  • Hepatitis B viral assembly effectors
    Patent number: 10273228
    Abstract: Novel assembly effector compounds having a therapeutic effect against hepatitis B viral (HBV) infection are disclosed. Assembly effector molecules described herein can lead to defective viral assembly and also may affect other viral activities associated with chronic HBV infection. Also disclosed is a process to synthesize disclosed compounds, method of treatment of HBV by administration of disclosed compounds, and use of these compounds in the manufacture of medicaments against HBV.
    Type: Grant
    Filed: April 15, 2016
    Date of Patent: April 30, 2019
    Assignees: Indiana University Research and Technology Corporation, Assembly Biosciences, Inc.
    Inventors: Lee Daniel Arnold, Hans Maag, William W. Turner, Jr.
  • Thioacetate compounds, compositions and methods of use
    Patent number: 10266493
    Abstract: Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.
    Type: Grant
    Filed: June 15, 2011
    Date of Patent: April 23, 2019
    Assignee: Ardea Biosciences, Inc.
    Inventors: Samedy Ouk, Esmir Gunic, Jean-Michel Vernier, Chixu Chen